ATLAS HOUSENAVIGATE YOUR HEALTH
Weight Management / Treatment Information

WEIGHT MANAGEMENT / TREATMENT INFORMATION

Understanding
your options.

Prescription treatment may form one part of weight-management care where it is clinically appropriate. The treatment considered will depend on factors including your health, medical and medication history, treatment goals, preferences and individual circumstances.

No single medicine is right for everyone. The information below is designed to help you understand some of the treatment options that may be discussed following an appropriate clinical assessment.

COMPARE AT A GLANCE

The details, considered.

Administration and dose schedules. Suitability requires individual assessment.

Comparison of treatment administration and dose schedules
ConsiderationMounjaroWegovy InjectionWegovy TabletsFoundayo
Active ingredientTirzepatideSemaglutideSemaglutideOrforglipron
FormatSubcutaneous injectionSubcutaneous injectionTabletTablet
FrequencyOnce weeklyOnce weeklyOnce dailyOnce daily
Main receptor activityGIP + GLP-1GLP-1GLP-1GLP-1
Initial dose2.5 mg weekly0.25 mg weekly1.5 mg daily0.8 mg daily
EscalationAt intervals of at least 4 weeksStandard schedule usually escalates every 4 weeksUsually monthly through the licensed dose stepsAt intervals of at least 30 days
AdministrationWeekly injectionWeekly injectionEmpty stomach with specific fasting/water timingCan be taken with or without food

Mounjaro

Active ingredient
Tirzepatide
Format
Subcutaneous injection
Frequency
Once weekly
Main receptor activity
GIP + GLP-1
Initial dose
2.5 mg weekly
Escalation
At intervals of at least 4 weeks
Administration
Weekly injection

Wegovy Injection

Active ingredient
Semaglutide
Format
Subcutaneous injection
Frequency
Once weekly
Main receptor activity
GLP-1
Initial dose
0.25 mg weekly
Escalation
Standard schedule usually escalates every 4 weeks
Administration
Weekly injection

Wegovy Tablets

Active ingredient
Semaglutide
Format
Tablet
Frequency
Once daily
Main receptor activity
GLP-1
Initial dose
1.5 mg daily
Escalation
Usually monthly through the licensed dose steps
Administration
Empty stomach with specific fasting/water timing

Foundayo

Active ingredient
Orforglipron
Format
Tablet
Frequency
Once daily
Main receptor activity
GLP-1
Initial dose
0.8 mg daily
Escalation
At intervals of at least 30 days
Administration
Can be taken with or without food

The medicines differ in their active ingredients, how they are taken, dose schedules and other clinical considerations. Suitability is assessed individually rather than by selecting a medicine from a table.

Current treatment costs

Treatment is prescribed only where clinically appropriate following assessment. The options and prices below are provided for factual information and are not recommendations to select a particular medicine.

Consultation and prescription fees are already included in our weight-management pen prices. No separate Atlas House consultation or prescription fee is added to those pen prices. Any separate charges are confirmed before payment.

Mounjaro

Tirzepatide · Subcutaneous injection

Mounjaro strengths and prices
StrengthPrice
2.5 mg£175
5 mg£195
7.5 mg£245
10 mg£275
12.5 mg£295
15 mg£310

Foundayo

Orforglipron · Tablet

Foundayo strengths and prices
StrengthPrice
0.8 mg£110
2.5 mg£120
5.5 mg£140
9 mg£160
14.5 mg£180
17.2 mg£190

Wegovy injection

Semaglutide · Subcutaneous injection

Wegovy injection strengths and prices
StrengthPrice
0.25 mg£125
0.5 mg£135
1 mg£145
1.7 mg£185
2.4 mg£225
7.2 mg£270

Wegovy tablets

Semaglutide · Tablet

Wegovy tablets strengths and prices
StrengthPrice
1.5 mg£115
4 mg£130
9 mg£155
25 mg£195

Your Atlas House service

Individual clinical assessment and prescribing review, ongoing clinician review and personalised treatment monitoring. Nutrition guidance is included where appropriate, with access to Atlas House support. Access your treatment details through the Atlas House patient portal.

Our pharmacy partner dispenses and supplies the medicine. Treatment is subject to clinical assessment and prescribing suitability.

Last reviewed: September 2026